Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: A meta-analysis

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1768-1777

  Xiao, Chun ^a,b,c   Zhou, Shijie ^b,c   Liu, Yueqiang ^b,c   Hu, Huozhen ^a,b,c  

^a SICHUAN UNIVERSITY   (China)

^b Department of Medicine Sichuan Scientific and Cellular Biotechnology Research Institute   (China)

^c Emei Mid level Qiliping Anti aging Research Center   (China)

Author keywords

Mesenchymal stromal cells; Meta analysis; Myocardial ischemia

Indexed keywords

ALDEHYDE DEHYDROGENASE;

ARTICLE; BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICULOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SAFETY; SYSTEMATIC REVIEW; THERAPY EFFECT; ADVERSE EFFECTS; CHRONIC DISEASE; DIASTOLE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PUBLISHING; SYSTOLE; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DIASTOLE; HUMANS; MYOCARDIAL ISCHEMIA; PUBLICATION BIAS; STROKE VOLUME; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84908129923     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892047     Document Type: Article

References (41)

1. Roger VL, Go AS, Lloyd-Jones DM et al: Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation, 2011; 123: e18–e209
2. Blecker S, Paul M, Taksler G et al: Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol, 2013; 61: 1259–67
3. Burt RK, Loh Y, Pearce W et al: Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA, 2008; 299: 925–36
4. Strauer BE, Brehm M, Zeus T et al: [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Dtsch Med Wochenschr, 2001;126: 932–38 [in German]
5. Dai W, Kloner RA: Bone marrow-derived cell transplantation therapy for myocardial infarction: lessons learned and future questions. Am J Transplant, 2011; 11: 2297–301
6. Tse HF, Thambar S, Kwong YL et al: Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J, 2007; 28: 2998–3005
7. Lalu MM, McIntyre L, Pugliese C et al: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PloS one, 2012; 7: e47559
8. Sun L, Zhang T, Lan X et al: Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a meta-analysis. Clin Cardiol, 2010; 33: 296–302
9. Perin EC, Silva GV, Henry TD et al: A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J, 2011; 161: 1078–87 e3
10. Hendrikx M, Hensen K, Clijsters C et al: Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation, 2006; 114: I101–7
11. Fisher SA, Doree C, Brunskill SJ et al: Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis. PloS one, 2013; 8: e64669
12. Xu R, Ding S, Zhao Y et al: Autologous Transplantation of Bone Marrow/ Blood-Derived Cells for Chronic Ischemic Heart Disease: A Systematic Review and Meta-analysis. Can J Cardiol, 2014; pii: S0828-282X(14)00044-0
13. Jeevanantham V, Butler M, Saad A et al: Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation, 2012; 126: 551–68
14. Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ, 2001; 323: 42–46
15. Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions Version 5.1: The Cochrane Collaboration, 2011
16. Heldman AW, DiFede DL, Fishman JE et al: Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA, 2014; 311: 62–73
17. Lu M, Liu S, Zheng Z et al: A pilot trial of autologous bone marrow mononuclear cell transplantation through grafting artery: a sub-study focused on segmental left ventricular function recovery and scar reduction. Int J Cardiol, 2013; 168: 2221–27
18. Maureira P, Tran N, Djaballah W et al: Residual viability is a predictor of the perfusion enhancement obtained with the cell therapy of chronic myocardial infarction: a pilot multimodal imaging study. Clin Nucl Med, 2012; 37: 738–42
19. Patel AN, Geffner L, Vina RF et al: Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg, 2005; 130: 1631–38
20. Perin EC, Willerson JT, Pepine CJ et al: Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA, 2012; 307: 1717–26
21. Pokushalov E, Romanov A, Chernyavsky A et al: Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J Cardiovasc Transl Res, 2010; 3: 160–68
22. Stamm C, Kleine HD, Choi YH et al: Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg, 2007; 133: 717–25
23. van Ramshorst J, Bax JJ, Beeres SL et al: Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA, 2009; 301: 1997–2004
24. Yao K, Huang R, Qian J et al: Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart, 2008; 94: 1147–53
25. Zhao Q, Sun Y, Xia L et al: Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg, 2008; 86: 1833–40
26. Ang KL, Chin D, Leyva F et al: Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med, 2008; 5: 663–70
27. Assmus B, Honold J, Schachinger V et al: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med, 2006; 355: 1222–32
28. Bartunek J, Behfar A, Dolatabadi D et al: Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart fail- URE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol, 2013; 61: 2329–38
29. Perin EC, Silva GV, Zheng Y et al: Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J, 2012; 163: 415–21, 21 e1
30. Nasseri BA, Ebell W, Dandel M et al: Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trialdagger. Eur HeartJ, 2014; 35: 1263–74
31. Patila T, Lehtinen M, Vento A et al: Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: A prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J Heart Lung Transplant, 2014; 33: 567–74
32. Chen S, Liu Z, Tian N et al: Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol, 2006; 18: 552–56
33. Brunskill SJ, Hyde CJ, Doree CJ et al: Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail, 2009; 11: 887–96
34. Perin EC, Silva GV, Assad JA et al: Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol, 2008; 44: 486–95
35. Orlic D, Kajstura J, Chimenti S et al: Bone marrow cells regenerate infarcted myocardium. Nature, 2001; 410: 701–5
36. Murry CE, Soonpaa MH, Reinecke H et al: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature, 2004; 428: 664–68
37. Hatzistergos KE, Quevedo H, Oskouei BN et al: Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res, 2010; 107: 913–22
38. Yang S, Piao J, Jin L et al: Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy? Med Sci Monit Basic Res, 2013; 19: 20–31
39. Orlic D, Kajstura J, Chimenti S et al: Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant, 2003; 7(Suppl 3): 86–88
40. Kocher AA, Schuster MD, Szabolcs MJ et al: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med, 2001; 7: 430–36
41. Hare JM, Fishman JE, Gerstenblith G et al: Comparison of allogeneic vs. autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA, 2012; 308: 2369–79